Erik Fink Eriksen

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. pmc Cellular mechanisms of bone remodeling
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514 Oslo, Norway
    Rev Endocr Metab Disord 11:219-27. 2010
  2. pmc Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta
    Lena Lande Wekre
    TRS National Resource Centre for Rare Disorders, Sunnaas Rehabilitation Hospital, Nesoddtangen, Norway
    Arch Osteoporos 6:31-8. 2011
  3. doi request reprint New developments in the treatment of osteoporosis
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Oslo, Norway
    Acta Obstet Gynecol Scand 92:620-36. 2013
  4. pmc Treatment of osteopenia
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514, Oslo, Norway
    Rev Endocr Metab Disord 13:209-23. 2012
  5. ncbi request reprint Hormone replacement therapy or SERMS in the long term treatment of osteoporosis
    E F Eriksen
    Department of Endocrinology, Oslo University Hospital, Oslo, Norway
    Minerva Ginecol 64:207-21. 2012
  6. pmc The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
    Astrid K Stunes
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
    BMC Endocr Disord 11:11. 2011
  7. pmc Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
    Stine Marit Moen
    Department of Neurology, Oslo University Hospital Ulleval, Oslo, Norway
    PLoS ONE 7:e45703. 2012
  8. doi request reprint Bone marrow lesions: a universal bone response to injury?
    Erik Fink Eriksen
    Department of Endocrinology, Oslo University Hospital, P O Box 4956 Nydalen, 0424 Oslo, Norway
    Rheumatol Int 32:575-84. 2012

Collaborators

  • Leiv Sandvik
  • Magritt Brustad
  • Trygve Holm√ły
  • Stine Marit Moen
  • Lena Lande Wekre
  • Astrid K Stunes
  • Lars Nordsletten
  • Elisabeth Gulowsen Celius
  • Bjorn I Gustafsson
  • Christiane Petzold
  • Unni Syversen
  • Reidar Fossmark
  • Jan H Waarsing
  • Irene Westbroek
  • Janne E Reseland
  • Jan A Falch

Detail Information

Publications8

  1. pmc Cellular mechanisms of bone remodeling
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514 Oslo, Norway
    Rev Endocr Metab Disord 11:219-27. 2010
    ..The dominant pathway regulating osteoclast recruitment is the RANKL/OPG system, while many different factors (RUNX, Osterix) are involved in osteoblast differentiation. Both pathways are modulated by calcitropic hormones...
  2. pmc Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta
    Lena Lande Wekre
    TRS National Resource Centre for Rare Disorders, Sunnaas Rehabilitation Hospital, Nesoddtangen, Norway
    Arch Osteoporos 6:31-8. 2011
    ..We found a surprising low prevalence (10%) of osteoporosis. These patients, however, expressed the most severe disease...
  3. doi request reprint New developments in the treatment of osteoporosis
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Oslo, Norway
    Acta Obstet Gynecol Scand 92:620-36. 2013
    ..Owing to cost and the need for parenteral administration, in most countries these agents are reserved for severe osteoporosis with multiple fractures...
  4. pmc Treatment of osteopenia
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514, Oslo, Norway
    Rev Endocr Metab Disord 13:209-23. 2012
    ....
  5. ncbi request reprint Hormone replacement therapy or SERMS in the long term treatment of osteoporosis
    E F Eriksen
    Department of Endocrinology, Oslo University Hospital, Oslo, Norway
    Minerva Ginecol 64:207-21. 2012
    ....
  6. pmc The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
    Astrid K Stunes
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
    BMC Endocr Disord 11:11. 2011
    ..abstract:..
  7. pmc Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
    Stine Marit Moen
    Department of Neurology, Oslo University Hospital Ulleval, Oslo, Norway
    PLoS ONE 7:e45703. 2012
    ..The aim of this study was to explore the mechanism of the low bone mass in early-stage MS patients...
  8. doi request reprint Bone marrow lesions: a universal bone response to injury?
    Erik Fink Eriksen
    Department of Endocrinology, Oslo University Hospital, P O Box 4956 Nydalen, 0424 Oslo, Norway
    Rheumatol Int 32:575-84. 2012
    ..We also try to pair this hypothesis with the apparent beneficial effects of various treatment regimens, mainly within the group of bone antiresorptive drugs (calcitonin, bisphosphonates) on symptoms associated with BMLs...